<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p88" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_88{left:130px;bottom:1195px;letter-spacing:0.22px;}
#t2_88{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_88{left:141px;bottom:1104px;letter-spacing:-0.01px;}
#t4_88{left:248px;bottom:1104px;letter-spacing:0.25px;}
#t5_88{left:143px;bottom:1047px;letter-spacing:-0.29px;}
#t6_88{left:250px;bottom:1067px;letter-spacing:-0.01px;}
#t7_88{left:250px;bottom:1047px;letter-spacing:-0.01px;}
#t8_88{left:250px;bottom:1028px;letter-spacing:-0.01px;}
#t9_88{left:248px;bottom:992px;letter-spacing:-0.04px;}
#ta_88{left:141px;bottom:928px;letter-spacing:-0.01px;}
#tb_88{left:248px;bottom:928px;letter-spacing:0.12px;}
#tc_88{left:141px;bottom:896px;letter-spacing:0.22px;}
#td_88{left:250px;bottom:891px;letter-spacing:-0.01px;}
#te_88{left:250px;bottom:872px;letter-spacing:-0.01px;}
#tf_88{left:250px;bottom:853px;letter-spacing:-0.01px;}
#tg_88{left:325px;bottom:853px;letter-spacing:-0.01px;}
#th_88{left:347px;bottom:853px;}
#ti_88{left:143px;bottom:848px;}
#tj_88{left:141px;bottom:813px;letter-spacing:-0.03px;}
#tk_88{left:248px;bottom:813px;letter-spacing:-0.03px;}
#tl_88{left:141px;bottom:766px;letter-spacing:-0.3px;}
#tm_88{left:248px;bottom:738px;letter-spacing:-0.04px;}
#tn_88{left:141px;bottom:667px;letter-spacing:-0.01px;}
#to_88{left:248px;bottom:668px;letter-spacing:0.12px;}
#tp_88{left:141px;bottom:635px;letter-spacing:0.22px;}
#tq_88{left:250px;bottom:630px;letter-spacing:-0.01px;}
#tr_88{left:250px;bottom:611px;letter-spacing:-0.01px;}
#ts_88{left:250px;bottom:592px;letter-spacing:-0.01px;}
#tt_88{left:143px;bottom:587px;}
#tu_88{left:141px;bottom:552px;letter-spacing:-0.03px;}
#tv_88{left:248px;bottom:552px;letter-spacing:-0.03px;}
#tw_88{left:141px;bottom:505px;letter-spacing:-0.3px;}
#tx_88{left:248px;bottom:478px;letter-spacing:-0.04px;}
#ty_88{left:238px;bottom:418px;letter-spacing:-0.01px;}
#tz_88{left:238px;bottom:398px;letter-spacing:-0.01px;}
#t10_88{left:238px;bottom:379px;letter-spacing:-0.01px;}
#t11_88{left:238px;bottom:359px;letter-spacing:-0.01px;}
#t12_88{left:238px;bottom:340px;letter-spacing:-0.01px;}
#t13_88{left:238px;bottom:286px;letter-spacing:-0.01px;}
#t14_88{left:238px;bottom:267px;letter-spacing:-0.01px;}
#t15_88{left:238px;bottom:247px;letter-spacing:-0.01px;}
#t16_88{left:238px;bottom:228px;letter-spacing:-0.01px;}
#t17_88{left:238px;bottom:208px;letter-spacing:-0.01px;}
#t18_88{left:238px;bottom:189px;letter-spacing:-0.01px;}
#t19_88{left:238px;bottom:169px;letter-spacing:-0.01px;}
#t1a_88{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_88{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_88{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_88{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_88{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_88{font-size:10px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_88{font-size:8px;font-family:NotoSans-Regular_7j-;color:#000;}
.s6_88{font-size:13px;font-family:NotoSans-Regular_7j-;color:#F78C00;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts88" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg88Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg88" style="-webkit-user-select: none;"><object width="908" height="1286" data="88/88.svg" type="image/svg+xml" id="pdf88" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_88" class="t s0_88">7.7. Residual tumor, recurrence and recurrent metastasis </span><span id="t2_88" class="t s1_88">88 </span>
<span id="t3_88" class="t s2_88">7.57. </span><span id="t4_88" class="t s0_88">Consensus-based recommendation </span>
<span id="t5_88" class="t s3_88">EEC </span>
<span id="t6_88" class="t s2_88">If a residual tumor remains after organ-preserving primary radiochemotherapy for </span>
<span id="t7_88" class="t s2_88">advanced laryngeal carcinoma, a salvage laryngectomy and, if necessary, a salvage neck </span>
<span id="t8_88" class="t s2_88">dissection should be performed. </span>
<span id="t9_88" class="t s4_88">Strong consensus: 100% </span>
<span id="ta_88" class="t s2_88">7.58. </span><span id="tb_88" class="t s1_88">Evidence-based recommendation </span>
<span id="tc_88" class="t s5_88">Recommendation level </span>
<span id="td_88" class="t s2_88">If a positive PET lymph node finding is present after 12 weeks of primary radio- </span>
<span id="te_88" class="t s2_88">chemotherapy, a neck dissection should be performed depending on the resectability </span>
<span id="tf_88" class="t s2_88">(see chapter</span><span id="tg_88" class="t s6_88">7.4 </span><span id="th_88" class="t s2_88">). </span>
<span id="ti_88" class="t s3_88">B </span>
<span id="tj_88" class="t s4_88">Level of Evidence </span><span id="tk_88" class="t s4_88">[114] </span>
<span id="tl_88" class="t s3_88">1b </span>
<span id="tm_88" class="t s4_88">Strong consensus: 100% </span>
<span id="tn_88" class="t s2_88">7.59. </span><span id="to_88" class="t s1_88">Evidence-based recommendation </span>
<span id="tp_88" class="t s5_88">Recommendation level </span>
<span id="tq_88" class="t s2_88">If PET-negative lymph node findings are present after 12 weeks of primary </span>
<span id="tr_88" class="t s2_88">radiochemotherapy, neck dissection should not be performed, but clinical and imaging </span>
<span id="ts_88" class="t s2_88">follow-up should be performed. </span>
<span id="tt_88" class="t s3_88">B </span>
<span id="tu_88" class="t s4_88">Level of Evidence </span><span id="tv_88" class="t s4_88">[114] </span>
<span id="tw_88" class="t s3_88">1b </span>
<span id="tx_88" class="t s4_88">Strong consensus: 100% </span>
<span id="ty_88" class="t s2_88">In an unblinded, prospective and randomized multicenter study, the reliable selection of </span>
<span id="tz_88" class="t s2_88">patients after radiochemotherapy who did not benefit from neck dissection was tested using </span>
<span id="t10_88" class="t s2_88">FDG-PET-CT [114]. In March 2017, the Federal Joint Committee announced the change in the </span>
<span id="t11_88" class="t s2_88">guideline on methods of statutory health insurance care using positron emission tomography </span>
<span id="t12_88" class="t s2_88">(PET)/computed tomography (CT) for head and neck tumors [294]. </span>
<span id="t13_88" class="t s2_88">The primary study endpoint was overall survival. 37 centers in Great Britain were involved. The </span>
<span id="t14_88" class="t s2_88">study population consisted of 564 patients with stage N2 and N3 head and neck tumors and </span>
<span id="t15_88" class="t s2_88">no evidence of distant metastases. These were randomized into 2 groups (surveillance group </span>
<span id="t16_88" class="t s2_88">(subgroup n=18 laryngeal carcinomas), planned neck dissection group (subgroup n=19 </span>
<span id="t17_88" class="t s2_88">laryngeal carcinomas)) of 282 patients each. Both groups were comparable. In the surveillance </span>
<span id="t18_88" class="t s2_88">group, neck dissection was performed depending on the FDG-PET-CT findings 3 months after </span>
<span id="t19_88" class="t s2_88">completion of radiochemotherapy. </span>
<span id="t1a_88" class="t s0_88">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
